BiotechTube
Citius Pharmaceuticals

Citius Pharmaceuticals

CTXRPhase 2
Cranford, United StatesFounded 2007citiuspharma.com

Citius Pharmaceuticals is a publicly traded, late-stage biopharma company focused on addressing unmet needs in critical care and oncology. The company has built a diversified pipeline with three main candidates, including the recently FDA-approved LYMPHIR™. With significant founder investment and a focus on products with large market potential, Citius aims to bring novel therapies to market faster.

Market Cap
$738.4M
Pipeline
2
drug candidates
Patents
—
Publications
—

AI Company Overview

Citius Pharmaceuticals is a publicly traded, late-stage biopharma company focused on addressing unmet needs in critical care and oncology. The company has built a diversified pipeline with three main candidates, including the recently FDA-approved LYMPHIR™. With significant founder investment and a focus on products with large market potential, Citius aims to bring novel therapies to market faster.

OncologyCritical CareInfectious DiseaseDermatologyGastroenterology

Technology Platform

Citius develops individual therapeutic candidates using various modalities rather than a single platform, focusing on late-stage or approved assets for critical care and oncology indications.

Pipeline

2
2 drugs in pipeline
DrugIndicationStageWatch
Monad 1 + Monad 2 + Monad 3 + Combination - CITI-002 (low do...HemorrhoidsPhase 2
Hydrocortisone acetate and lidocaine hydrochloride + Placebo...HemorrhoidsPhase 2

Opportunities

Citius has immediate revenue potential with FDA-approved LYMPHIR™ and significant future opportunity with Mino-Lok® targeting a $1.8 billion market.
The company's diversified pipeline across critical care and oncology provides multiple shots on goal for value creation.

Risk Factors

Key risks include clinical trial failure for Phase 3 candidate Mino-Lok®, commercialization challenges for newly approved LYMPHIR™, future financing needs potentially diluting shareholders, and competitive pressures across all therapeutic areas.

Competitive Landscape

Citius competes in niche markets with unmet needs: LYMPHIR™ faces competition from other CTCL therapies, while Mino-Lok® would compete against standard antibiotic lock therapies and catheter replacement. Differentiation comes from novel mechanisms and focus on catheter salvage in CRBSIs.